News

2015 WGND Annual Meeting and Reception


22 Nov 2015
by Working Group

Cape Town, South Africa, Dec. 5, 17:30 – 20:30

We invite you to join us for the Stop TB Partnership Working Group on New Drugs’ Annual Meeting 2015 at Southern Sun Cape Sun Hotel, Cape Town, South Africa, on Saturday, Dec. 5th from 17:30 to 20:30.

This meeting is held before the 46th Union World Conference on Lung Health (The Union). During the meeting we will review and discuss progress of projects in the Global TB Drug Pipeline and Drug Discovery Portfolio, the new Global Plan, review WGND 2015 activities, and discuss other relevant topics. Representatives from pharmaceutical companies, research consortia and organizations, NGOs and academia will be participating.

2015 WGND ANNUAL MEETING

Agenda

17:30 – 17:35

Welcome Mel Spigelman

17:35 – 17:40

Stop TB Partnership, Global Plan Cherise Scott

17:40 – 17:50

TB Drug Development Year-in-Review Barbara Laughon
Global Pipeline Update

17:50 – 18:00

Janssen Myriam Haxaire

18:05 – 18:15

Clinical Trials Unit, MRC Andrew Nunn

18:20 – 18:30

TB Alliance Christo van Niekerk

18:35 – 18:45

AIDS Clinical Trials Group (ACTG) Susan Swindells

18:50 – 19:00

NIAID – Host-Directed Therapy Richard Hafner

19:05 – 19:15

University of Munich / EDCTP/PanACEA Michael Hoelscher & Martin Boeree

19:20 – 19:30

TB Trials Consortium (CDC) Neil Schluger
Looking Forward

19:35 – 19:50

Discussion of STOP TB Partnership Association Mel Spigelman, Cherise Scott, Barbara Laughon

19:50 – 20:30

Cocktail Reception WGND Members

Saturday, December 5th, 2015 | 17:30 – 20:30

Southern Sun Cape Sun Hotel| Cape Town, South Africa

Heavy hors d’oeuvres and drinks will be served.

Registration is free.

Please register by sending an e-mail reply to wgnd@newtbdrugs.org.

If you have any questions, please feel free to contact me.

Explore. Learn. Join the Conversation at www.newtbdrugs.org.
Best regards,

Cherise Scott, WGND Secretariat

More News
11 Apr 2017
Scientist at Rutgers University and their collaborators have published an article in Molecular Cell illustrating the three-dimensional structure of the drug target for the drug rifampicin. The abstract for the article is below. TITLE: Structural Basis of Mycobacterium tuberculosis Transcription and...
22 Mar 2017
March 21, 2017 Infectex Announces Positive Phase 2b-3 Clinical Trial Results of SQ109 for the Treatment of Multidrug-Resistant Pulmonary Tuberculosis Moscow, Russia and Rockville, MD, USA -- Infectex Ltd., a Russian portfolio company of Maxwell Biotech Venture Fund (MBVF), today announced positive...
10 Mar 2017
WGND Co-chair, Barbara Laughon, and Sequella Inc. CEO, Carol Nacy, co-authored a correspondence to Nature Reviews regarding the October 2016 Article, “Tuberculosis”. “In their recent Primer article (Tuberculosis. Nat. Rev. Dis. Primers 2, 16076 (2016))1, Madhukar Pai and colleagues give an...